Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06354140RecruitingPhase 2
Tislelizumab plus S-1 for esophageal cancer after surgery
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07801287RecruitingPhase 2
Combination treatment before and after surgery for intermediate-stage liver cancer
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
TianjinAges 18 years+ - NCT07806292RecruitingPhase 2
Combination therapy for inoperable liver cancer
This study tests a combination of two drugs (anlotinib and benmelstobart) with a liver-directed chemotherapy procedure (HAIC) in people with liver cancer that cannot be removed surgically. The goal is to see if this combo shrinks tumors and is safe.
Guangzhou, GuangdongAges 18–75 - NCT07803081Recruiting
Radiotherapy after breast surgery without lymph node biopsy
This study looks at how well radiation therapy works for women with early-stage breast cancer who had breast-conserving surgery but did not have their underarm lymph nodes removed. It aims to understand long-term outcomes and help guide future treatment decisions.
SeoulAges 19 years+ - NCT07808853RecruitingPhase 2
Short radiation plus chemo-immunotherapy before esophageal cancer surgery
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
Guanzhou, GuangdongAges 18–75 - NCT06138028RecruitingPhase 2/Phase 3
Sintilimab plus chemo and radiation for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Qingdao, ShandongAges 18–80 - NCT06518434RecruitingPhase 2
Cannabis oil for advanced liver cancer study
This study tests if cannabis oil can help people with advanced liver cancer that cannot be treated with standard therapies. It is a small pilot study to see if the oil is safe and may improve symptoms or quality of life.
GroningenAges 18 years+ - NCT06518226Recruiting
Ultra-short radiation with focal boost for prostate cancer
This trial tests a new, shorter course of radiation for intermediate-risk prostate cancer. It aims to give a higher dose to the main tumor while keeping side effects low.
UtrechtAges 18 years+ - NCT07796672Recruiting
Blood test study for cervical cancer biomarkers
This study is looking for markers in the blood of people with cervical cancer that might help doctors choose the best treatment. It is a feasibility study, meaning it aims to find out if this approach works before a larger trial.
Brisbane, QueenslandAges 18 years+ - NCT07796113RecruitingPhase 2
Study of adebrelimab plus famitinib and chemo before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (famitinib) with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Xi'an, ShannxiAges 18–75 - NCT07794813Recruiting
Imaging agent for clearer tumor removal in oral cancer surgery
This study tests a new imaging agent that helps surgeons see oral tumors more clearly during surgery. It aims to improve the accuracy of tumor removal.
Kunming, YunnanAges 18–75 - NCT07796880RecruitingPhase 2
Study of a new drug with hormone therapy before breast cancer surgery
This trial tests a new drug called culmerciclib when given with hormone therapy before breast cancer surgery. The goal is to see if this combination can shrink tumors and improve outcomes for patients with hormone-receptor-positive, HER2-negative breast cancer.
Guangzhou, GuangdongAges 18–70 - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT06393816RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC lung cancer
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Aix-en-ProvenceAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT07784959RecruitingPhase 1
Study of NXP900 with lorlatinib for ALK-positive lung cancer
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
Fairfax, VirginiaAges Any age - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07782164Recruiting
Irreversible electroporation for recurrent pelvic tumors
This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.
Amsterdam, North HollandAges 18 years+ - NCT07781137Recruiting
Long-term outcomes of endoscopic removal of duodenal and ampullary growths
This study looks at how well people do over time after having non-cancerous or early-stage growths in the duodenum or ampulla removed during an endoscopy. It aims to understand the long-term safety and effectiveness of this procedure.
Sydney, New South WalesAges 18 years+ - NCT06553339RecruitingPhase 1
A study of HS-10516 for VHL syndrome tumors
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
Beijing, Beijing MunicipalityAges 18–80 - NCT06560827RecruitingPhase 1
CAR-T Cells for Liver Cancer After Surgery
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
BeijingAges 18–75 - NCT06561399Recruiting
Triple therapy followed by radiation for liver cancer
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
Fuzhou, FujianAges 18–75 - NCT02511288Recruiting
Blood tests to monitor advanced lung cancer during care
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
AnnecyAges 18 years+ - NCT04770207RecruitingPhase 2
Injecting a cancer drug mixture directly into tumors
This Phase 2 study tests a treatment where drug-loaded tiny beads are injected into a solid tumor, using more than one medicine. It may help people with advanced solid cancers by delivering the drugs right at the tumor site.
Guangzhou, GuangdongAges 18–99
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,124 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.